<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00525096</url>
  </required_header>
  <id_info>
    <org_study_id>CELAROM</org_study_id>
    <nct_id>NCT00525096</nct_id>
  </id_info>
  <brief_title>Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer</brief_title>
  <official_title>A Multicenter Randomized Phase III, Double-blind Study Comparing Efficacy of the Association of Exemestane and Celecoxib Versus Exemestane and Placebo in Menopausal Patients With Metastatic Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ARCAGY/ GINECO GROUP</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To discover if the adding of a coxib increases the efficacy of the Aromasine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality Of Life + pain</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">157</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Aromasin + placebo in place of Celebrex</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celebrex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aromasin + Celebrex</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>2 tablets twice a day per os</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>2*200 mg tablets twice a day per os</description>
    <arm_group_label>Celebrex</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <description>Exemestane 25 mg per day per os</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Celebrex</arm_group_label>
    <other_name>Aromasin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Femal patient aged &gt; 18 years

          -  Histologically proven breast cancer

          -  Menopausal patient according to the following definition:

               -  amenorrhoea &gt; 1 year or menopause affirmed by a rate of oestradiol or hypophyseal
                  gonadotrophin

               -  surgical ovariectomy

               -  treatment by LHRH analog

               -  ovarian suppression by radiotherapy

               -  amenorrhoea induced by chemotherapy &gt; 1 year

          -  Oestradiol and/or progesterone positive receptors

          -  Presence of one or several metastatic lesion:

               -  mesurable lesion

               -  bone metastase were detected by bone scintigraphy

          -  Patient who can have received:

               -  Adjuvant chemotherapy and/or hormonotherapy (Tamoxifen)

               -  Metastatic Treatment by chemotherapy

          -  PS &lt; 2

          -  Adequate biological values

          -  Patient who has clearly given her consent by signing on informed consent form prior to
             participation

        Exclusion Criteria:

          -  Patient previously treated with hormonotherapy in metastatic phase

          -  Antecedent of treatment with aromatase inhibitors

          -  local relapse (with the exception of cutaneous thoracic nodes)

          -  Patient with only one metastatic lesion like: pleurisy , ascites, lung Lymphangitis
             carcinomatosa
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles FREYER, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Lyon Sud - France</affiliation>
  </overall_official>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2007</study_first_submitted>
  <study_first_submitted_qc>September 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2007</study_first_posted>
  <last_update_submitted>June 29, 2011</last_update_submitted>
  <last_update_submitted_qc>June 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2011</last_update_posted>
  <responsible_party>
    <name_title>Benedicte VOTAN</name_title>
    <organization>ARCAGY-GINECO</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Exemestane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

